Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932256 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients
A Phase 1 study, sponsored by Magna Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00932256 is a Phase 1 study that has completed, run by Magna Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT00932256, a Phase 1 study, has completed, sponsored by Magna Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
MAGNA intends to show that the combination of pseudoephedrine, chlorpheniramine, plus a small amount of belladonna alkaloid is a comprehensive, safe and effective twice daily (BID) drug treatment for seasonal allergic rhinitis (SAR) patients with post-nasal drip (PND). The phase 1 single-dose trial will consist of 21 subjects: 1) to gather pharmacodynamic measurements and blood levels of active ingredients over 12 hours; 2) To report subjective scores by subjects rating efficacy of single dose of STAHIST; 3) To report any side effects or adverse drug reactions and rate the severity of incidence.
Interventions
- DRUG STAHIST NDC #58407-536-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932256
The ClinicalTrials.gov registry entry for NCT00932256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Magna Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STAHIST NDC #58407-536-01 is the first listed.
NCT00932256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932256 about?
NCT00932256 is a clinical study titled "Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients". MAGNA intends to show that the combination of pseudoephedrine, chlorpheniramine, plus a small amount of belladonna alkaloid is a comprehensive, safe and effective twice daily (BID) drug treatment for seasonal allergic rhinitis (SAR) patients with post-nasal drip (PND). The phase 1 single-dose trial ...
What is the current status of trial NCT00932256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2009-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00932256?
The interventions under investigation include: STAHIST NDC #58407-536-01 (DRUG).
Who is sponsoring clinical trial NCT00932256?
This trial is sponsored by Magna Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.